JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rickabaugh, T. M.
Right arrow Articles by Sun, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rickabaugh, T. M.
Right arrow Articles by Sun, R.

 Previous Article  |  Next Article 

Journal of Virology, September 2004, p. 9215-9223, Vol. 78, No. 17
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.17.9215-9223.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Generation of a Latency-Deficient Gammaherpesvirus That Is Protective against Secondary Infection

Tammy M. Rickabaugh,1 Helen J. Brown,2 DeeAnn Martinez-Guzman,1 Ting-Ting Wu,2 Leming Tong,2 Fuqu Yu,2 Steven Cole,1,3,4 and Ren Sun1,2,4,5*

Department of Molecular and Medical Pharmacology,2 Department of Medicine,3 UCLA AIDS Institute,4 Jonsson Comprehensive Cancer Center,5 Molecular Biology Institute, University of California at Los Angeles, Los Angeles, California1

Received 6 January 2004/ Accepted 22 April 2004

Kaposi's sarcoma-associated herpesvirus and murine gammaherpesvirus-68 (MHV-68) establish latent infections and are associated with various types of malignancies. They are members of the gamma-2 herpesvirus subfamily and encode a replication and transcriptional activator, RTA, which is necessary and sufficient to disrupt latency and initiate the viral lytic cycle in vitro. We have constructed a recombinant MHV-68 virus that overexpresses RTA. This virus has faster replication kinetics in vitro and in vivo, is deficient in establishing latency, exhibits a reduction in the development of a mononucleosis-like disease in mice, and can protect mice against challenge by wild-type MHV-68. The present study, by using MHV-68 as an in vivo model system, demonstrated that RTA plays a critical role in the control of viral latency and suggests that latency is a determinant of viral pathogenesis in vivo.

* Corresponding author. Mailing address: Department of Molecular and Medical Pharmacology, School of Medicine, 23-170 CHS, University of California at Los Angeles, 10833 Le Conte Ave., Los Angeles, CA 90095-1735. Phone: (310) 794-5557. Fax: (310) 825-6267. E-mail: rsun{at}mednet.ucla.edu.

Journal of Virology, September 2004, p. 9215-9223, Vol. 78, No. 17
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.17.9215-9223.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.